Clinical Spectrum and Therapeutic Options in Monogenic CTLA-4-, LRBA-, or SOCS1-Related Primary Immune Regulatory Disorders.
Primary immune regulatory disorders (PIRDs) are defined by a loss of immune homeostasis and are clinically characterized by autoimmunity, autoinflammation, lymphoproliferation, infection susceptibility, and cancer predisposition. An increasing number of genetic defects have been described that result in impaired regulation of immune responses.
Primary immune regulatory disorders (PIRDs) are defined by a loss of immune homeostasis and are clinically characterized by autoimmunity, autoinflammation, lymphoproliferation, infection susceptibility, and cancer predisposition. An increasing number of genetic defects have been described that result in impaired regulation of immune responses.
What the study was
- Study design
- Not specified
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- The journal of allergy and clinical immunology. In practice
Why it surfaced
Relevant Novel therapeutics: immunotherapy, CAR-T, targeted therapy study (promising preliminary signal) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.